At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 94 enrolled
Drug / intervention
Certolizumab Pegol +1 morebiological
Likely dose
Certolizumab Pegol 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Multi-center, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Assess the Safety and Efficacy of CDP870/Certolizumab Pegol, Dosed Subcutaneously in Patients With Active Crohn's Disease
In Brief
A Phase 2 clinical trial evaluating Certolizumab Pegol and Placebo for Crohn's Disease. Completed, enrolled 94 participants across 22 sites.
Detailed Summary
This is a multi-centre, randomized, double-blind, dose response clinical study of CDP870 in patients with Crohn's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2006
Enrollment StartMar 2006
Primary CompletionNov 2007
TodayJul 2026
First PostedFeb 14, 2006
Enrollment StartMar 2, 2006
Primary CompletionNov 8, 2007
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 20.4 years ago
Interventions
Certolizumab Pegolbiological
* Active Substance: Certolizumab Pegol * Pharmaceutical Form: Solution for injection in pre-filled syringe * Concentration: 200 mg/mL * Route of Administration: Subcutaneous use
Placeboother
* Active Substance: isotonic sodium chloride solution * Pharmaceutical Form: Solution for injection * Concentration: 1 mL * Route of Administration: Subcutaneous use